Intralink Insights

Micah Hostetter from our Energy & Environment Group has just had an article published in Open Access Government on China’s acute pollution problems and its environmental sector, which is growing at a lightning pace to address them.

So, here we are again! Last year ZTE; this year Huawei. Exactly how much trouble is the company in? What are its – and the Chinese government’s – options from here? And could there be big opportunities for European and Asian tech firms to step in to fill the void of banned US technologies?

In the heart of the country that invented the word “entrepreneur”, VivaTech, one of the largest startup events in Europe, kicked off last Thursday, welcoming more than 100,000 visitors from over 100 countries.

The world’s a faster place. Not only are we expected to succeed faster, we’re now expected to fail faster. That’s OK, provided you’re working in a market where it’s possible to succeed and fail fast.

For some years, Japan has lagged other developed markets in digital health, but the tide is decisively turning – making this an opportune time for western companies keen to make an impact in this potentially lucrative market.

Having been involved in many in vitro diagnostics (IVD) projects in China over the last year, I decided to look back and summarise the industry’s recent developments. It’s a complex market that’s changing significantly, with Chinese IVD companies rapidly becoming more mature and competitive.